Plain-English translation of NCT06758882 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether men with high-risk prostate cancer benefit from taking — a hormone-blocking medication — for 18 months after surgery. Half of the participants will receive the medication along with standard hormone therapy, and the other half will receive standard hormone therapy alone. Researchers want to understand if this additional medication can help prevent cancer from returning or spreading.
Some men with aggressive prostate cancer have a few distant spots of cancer that show up on advanced imaging but are missed by standard scans. This trial exists to see whether adding this medication after surgery can control those spots better and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You will have surgery to remove your prostate and nearby lymph nodes. Four weeks after surgery, you'll start either the medication plus standard hormone therapy or standard hormone therapy alone, depending on random assignment. You'll visit the clinic every 3 months for blood tests and check-ups, and have imaging scans yearly (or sooner if needed). The treatment phase lasts 18 months, followed by 6 months of follow-up visits. After that, you'll continue regular cancer follow-up care with your doctor.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Italy